Literature DB >> 22829698

Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C.

Vusumuzi Ncube1, Bryan Starkey, Tim Wang.   

Abstract

BACKGROUND: The increase in creatinine in patients on fibrate therapy is well-recognized, but its mechanism is not clearly understood. A study by Hottelart et al. suggested that fibrate-induced creatininaemia was due to the effect of fibrates on creatinine metabolism as opposed to a decline in renal function. To address this hypothesis, we have monitored renal function in a group of hyperlipidaemic patients before commencing fibrate treatment and after three months of therapy.
METHODS: We studied 12 subjects (10 men, 2 women), median age 43.5 y (range 33-70 y). Serum creatinine, cystatin C, creatine kinase and fasting lipids were measured.
RESULTS: We observed statistically significant increases in concentrations of serum creatinine (P < 0.005) and cystatin C(P < 0.01). Concentrations of both analytes increased in 10 (83.3%) of the patients. In these patients, the median increases were 15.1% (range 5.5-23.2%) for creatinine and 9.9% (range 1.1-26.1%) for cystatin C.
CONCLUSIONS: These results suggest that the decrease in estimated glomerular filtration rate, observed in patients undergoing fibrate therapy, is a genuine effect on kidney function rather than a change in creatinine metabolism as previously postulated, since the rises in serum creatinine concentration were reflected by rises in cystatin C, an independent marker of renal function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829698     DOI: 10.1258/acb.2012.011163

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  8 in total

1.  Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Authors:  Charlotte Koopal; A David Marais; Jan Westerink; Yolanda van der Graaf; Frank L J Visseren
Journal:  J Lipid Res       Date:  2017-09-19       Impact factor: 5.922

2.  Diabetes, bilirubin and amputations: is there a link?

Authors:  N Katsiki; A Karagiannis; D P Mikhailidis
Journal:  Diabetologia       Date:  2013-01-27       Impact factor: 10.122

3.  Assessment of Serum Cystatin C Levels in Newly Diagnosed Acute Myocardial Infarction at the Onset and at the Time of Hospital Discharge.

Authors:  Adil H Alhusseiny; Marwan S M Al-Nimer; Sarah Isam Attallah Al-Neamy
Journal:  Cardiol Res       Date:  2015-02-09

Review 4.  Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.

Authors:  Lin Wang; Yin Cai; Liguo Jian; Chi Wai Cheung; Liangqing Zhang; Zhengyuan Xia
Journal:  Cardiovasc Diabetol       Date:  2021-01-04       Impact factor: 9.951

5.  Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms.

Authors:  Naofumi Amioka; Toru Miyoshi; Tomoko Yonezawa; Megumi Kondo; Satoshi Akagi; Masashi Yoshida; Yukihiro Saito; Kazufumi Nakamura; Hiroshi Ito
Journal:  Front Cardiovasc Med       Date:  2022-06-30

Review 6.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.

Authors:  Shizuya Yamashita; Daisaku Masuda; Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2020-01-23       Impact factor: 5.113

7.  Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.

Authors:  Chie Iitake; Daisaku Masuda; Masahiro Koseki; Shizuya Yamashita
Journal:  Cardiovasc Diabetol       Date:  2020-11-27       Impact factor: 9.951

Review 8.  Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?

Authors:  Naofumi Amioka; Toru Miyoshi
Journal:  Biomolecules       Date:  2022-01-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.